Boston Cambridge Biotech Networks

BCBN Feed: Cellular traffic congestion in chronic diseases suggests new therapeutic targets https://lnkd.in/g6WmfEjD Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target. ... [...]

BCBN Feed: Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines https://lnkd.in/g4kDjcry MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #USPSTF--Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines ... [...]

BCBN Feed: Studies Show Phone-Based Customer Service in Healthcare Is Here to Stay https://lnkd.in/gyf7Uf_4 WOBURN, Mass., Dec. 10, 2024 /PRNewswire/ -- Report by Parlance: As health systems undertake digital transformation initiatives, they often make the mistake of prioritizing portals and chatbots and neglect the phone, the dominant means of consumer communication. The voice channel has... ... [...]

BCBN Feed: MassBioDrive launches Spring 2025 biotech application, announces plans to extend industry-leading support to ‘techbio’ companies in fall 2025 https://lnkd.in/gvWuA-pq The MassBioDrive program will host two cohorts in 2025, though each will focus on a different segment of the industry. Because of this, scientific founders or emerging biotech companies should apply for the Spring 2025 (S25) biotech cohort, which is now open for applications. The Fall 2025 (F25) cohort will... ... [...]

BCBN Feed: NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases https://lnkd.in/gVTr-9qU PALO ALTO, Calif. and SEOUL, South Korea, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Scilex Bio, a controlling interest of joint venture by Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”) today announced the signing of a binding term sheet with NeuroBiogen (“NB”) to grant Scilex Bio an exclusive worldwide license... ... [...]

BCBN Feed: Cambridge biotech raises $52M to bring cancer drug to clinic https://lnkd.in/gvu-wTec Regeneron Ventures and Cure Ventures have led a Series A investment in a Cambridge biotech looking to bring its first cancer drug into the clinic next year. ... [...]

BCBN Feed: VBI Vaccines Provides an Update on its Restructuring Proceedings and Announces Partial Revocation Order from the British Columbia Securities Commission https://lnkd.in/gR6sEeaG CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ - VBI Vaccines Inc. ("VBI" or the "Company") today provided an update on the restructuring proceedings announced on July 30, 2024. Restructuring Transaction Following the conclusion of the sale and investment solicitation process conducted... ... [...]

BCBN Feed: BostonGene Unveils Transformative Breast Cancer Research at 2024 San Antonio Breast Cancer Symposium, Showcasing Precision Tools for Tailored Treatment Approaches https://lnkd.in/gT9ZRy87 WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that three abstracts have been accepted for poster presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), to take place December 10 - 13, 2024, at the Henry B. Gonzalez Convention Center in San... ... [...]

BCBN Feed: MIT’s CSAIL Director Daniela Rus Awarded Prestigious Edison Medal https://lnkd.in/gkEiNdiT CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Computer Science and Artificial Intelligence Laboratory (CSAIL) at MIT announced that its director, Daniela Rus, has been awarded the 2025 Edison Medal from the Institute of Electrical and Electronics (IEEE). The award recognizes Rus’s “sustained leadership and pioneering contributions in modern robotics” and follows her 2023 Robotics... ... [...]

BCBN Feed: Cases of severe RSV in two Moderna vaccine candidates’ trials raise questions about future https://lnkd.in/gAjSTX6x Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children and infants are currently on hold, including two not previously disclosed by Moderna. ... ... [...]